Literature DB >> 2773932

A high proportion of ADA point mutations associated with a specific alanine-to-valine substitution.

M L Markert1, C Norby-Slycord, F E Ward.   

Abstract

In 15%-20% of children with severe combined immunodeficiency (SCID), the underlying defect is adenosine deaminase (ADA) deficiency. The overall goal of our research has been to identify the precise molecular defects in patients with ADA-deficient SCID. In this study, we focused on a patient whom we found to have normal sized ADA mRNA by Northern analysis and an intact ADA structural gene by Southern analysis. By cloning and sequencing this patient's ADA cDNA, we found a C-to-T point mutation in exon 11. This resulted in the amino acid substitution of a valine for an alanine at position 329 of the ADA protein. Sequence analysis revealed that this mutation created a new BalI restriction site. Using Southern analyses, we were able to directly screen individuals to determine the frequency of this mutation. By combining data on eight families followed at our institution with data on five other families reported in the literature, we established that five of 13 patients (seven of 22 alleles) with known or suspected point mutations have this defect. This mutation was found to be associated with three different ADA haplotypes. This argues against a founder effect and suggests that the mutation is very old. In summary, a conservative amino acid substitution is found in a high proportion of patients with ADA deficiency; this can easily be detected by Southern analysis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2773932      PMCID: PMC1683405     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  32 in total

1.  Adenosine deaminase (ADA) deficiency due to deletion of the ADA gene promoter and first exon by homologous recombination between two Alu elements.

Authors:  M L Markert; J J Hutton; D A Wiginton; J C States; R E Kaufman
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

2.  The CpG dinucleotide and human genetic disease.

Authors:  D N Cooper; H Youssoufian
Journal:  Hum Genet       Date:  1988-02       Impact factor: 4.132

3.  Structure of adenosine deaminase mRNAs from normal and adenosine deaminase-deficient human cell lines.

Authors:  G S Adrian; D A Wiginton; J J Hutton
Journal:  Mol Cell Biol       Date:  1984-09       Impact factor: 4.272

4.  Adenosine deaminase and purine nucleoside phosphorylase deficiencies: evaluation of therapeutic interventions in eight patients.

Authors:  M L Markert; M S Hershfield; R I Schiff; R H Buckley
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

5.  Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation.

Authors:  R H Buckley; S E Schiff; H A Sampson; R I Schiff; M L Markert; A P Knutsen; M S Hershfield; A T Huang; G H Mickey; F E Ward
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

6.  Severe combined immune deficiency due to a homozygous 3.2-kb deletion spanning the promoter and first exon of the adenosine deaminase gene.

Authors:  T M Berkvens; E J Gerritsen; M Oldenburg; C Breukel; J T Wijnen; H van Ormondt; J M Vossen; A J van der Eb; P Meera Khan
Journal:  Nucleic Acids Res       Date:  1987-11-25       Impact factor: 16.971

7.  Mutant human adenosine deaminase alleles and their expression by transfection into fibroblasts.

Authors:  A L Akeson; D A Wiginton; M R Dusing; J C States; J J Hutton
Journal:  J Biol Chem       Date:  1988-11-05       Impact factor: 5.157

8.  Identification of a point mutation in the adenosine deaminase gene responsible for immunodeficiency.

Authors:  D T Bonthron; A F Markham; D Ginsburg; S H Orkin
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

9.  Cloning of cDNA sequences of human adenosine deaminase.

Authors:  D A Wiginton; G S Adrian; R L Friedman; D P Suttle; J J Hutton
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

10.  One adenosine deaminase allele in a patient with severe combined immunodeficiency contains a point mutation abolishing enzyme activity.

Authors:  D Valerio; B M Dekker; M G Duyvesteyn; L van der Voorn; T M Berkvens; H van Ormondt; A J van der Eb
Journal:  EMBO J       Date:  1986-01       Impact factor: 11.598

View more
  7 in total

1.  Homozygosity for a newly identified missense mutation in a patient with very severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID).

Authors:  R Hirschhorn; V Chakravarti; J Puck; S D Douglas
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

2.  Diagnosis, Treatment and Long-Term Follow Up of Patients with ADA Deficiency: a Single-Center Experience.

Authors:  Renata Baffelli; Lucia D Notarangelo; Luisa Imberti; Michael S Hershfield; Federico Serana; Ines Santisteban; Federica Bolda; Fulvio Porta; Arnalda Lanfranchi
Journal:  J Clin Immunol       Date:  2015-09-16       Impact factor: 8.317

3.  Somatic mosaicism for a newly identified splice-site mutation in a patient with adenosine deaminase-deficient immunodeficiency and spontaneous clinical recovery.

Authors:  R Hirschhorn; D R Yang; A Israni; M L Huie; D R Ownby
Journal:  Am J Hum Genet       Date:  1994-07       Impact factor: 11.025

4.  Insulin-dependent diabetes mellitus and severe atopic dermatitis in a child with adenosine deaminase deficiency.

Authors:  L D Notarangelo; G Stoppoloni; R Toraldo; E Mazzolari; A Coletta; P Airò; C Bordignon; A G Ugazio
Journal:  Eur J Pediatr       Date:  1992-11       Impact factor: 3.183

5.  Haplotype analysis of the human apolipoprotein B mutation associated with familial defective apolipoprotein B100.

Authors:  E H Ludwig; B J McCarthy
Journal:  Am J Hum Genet       Date:  1990-10       Impact factor: 11.025

6.  Paradoxical expression of adenosine deaminase in T cells cultured from a patient with adenosine deaminase deficiency and combine immunodeficiency.

Authors:  F X Arredondo-Vega; J Kurtzberg; S Chaffee; I Santisteban; E Reisner; M S Povey; M S Hershfield
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

7.  Distinct states of proinsulin misfolding in MIDY.

Authors:  Leena Haataja; Anoop Arunagiri; Anis Hassan; Kaitlin Regan; Billy Tsai; Balamurugan Dhayalan; Michael A Weiss; Ming Liu; Peter Arvan
Journal:  Cell Mol Life Sci       Date:  2021-07-10       Impact factor: 9.261

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.